A carregar...
Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
Unlike chemoimmunotherapy regimens, which are given for a defined period, ibrutinib, a first‐in‐class Bruton's kinase inhibitor, allows most patients with CLL to remain on treatment for an extended period. Our experience, supported by sequential CT scan images, suggests that long‐term ibrutinib...
Na minha lista:
| Publicado no: | Clin Case Rep |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5224778/ https://ncbi.nlm.nih.gov/pubmed/28096995 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.749 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|